TY - JOUR
T1 - Assessment of antiviral properties of peramivir against H7N9 avian influenza virus in an experimental mouse model
AU - Farooqui, Amber
AU - Huang, Linxi
AU - Wu, Suwu
AU - Cai, Yingmu
AU - Su, Min
AU - Lin, Pengzhou
AU - Chen, Weihong
AU - Fang, Xibin
AU - Zhang, Li
AU - Liu, Yisu
AU - Zeng, Tiansheng
AU - Paquette, Stephane G.
AU - Khan, Adnan
AU - Kelvin, Alyson A.
AU - Kelvina, David J.
N1 - Publisher Copyright:
Copyright © 2015 Farooqui et al.
PY - 2015/12/1
Y1 - 2015/12/1
N2 - The H7N9 influenza virus causes a severe form of disease in humans. Neuraminidase inhibitors, including oral oseltamivir and injectable peramivir, are the first choices of antiviral treatment for such cases; however, the clinical efficacy of these drugs is questionable. Animal experimental models are essential for understanding the viral replication kinetics under the selective pressure of antiviral agents. This study demonstrates the antiviral activity of peramivir in a mouse model of H7N9 avian influenza virus infection. The data show that repeated administration of peramivir at 30 mg/kg of body weight successfully eradicated the virus from the respiratory tract and extrapulmonary tissues during the acute response, prevented clinical signs of the disease, including neuropathy, and eventually protected mice against lethal H7N9 influenza virus infection. Early treatment with peramivir was found to be associated with better disease outcomes.
AB - The H7N9 influenza virus causes a severe form of disease in humans. Neuraminidase inhibitors, including oral oseltamivir and injectable peramivir, are the first choices of antiviral treatment for such cases; however, the clinical efficacy of these drugs is questionable. Animal experimental models are essential for understanding the viral replication kinetics under the selective pressure of antiviral agents. This study demonstrates the antiviral activity of peramivir in a mouse model of H7N9 avian influenza virus infection. The data show that repeated administration of peramivir at 30 mg/kg of body weight successfully eradicated the virus from the respiratory tract and extrapulmonary tissues during the acute response, prevented clinical signs of the disease, including neuropathy, and eventually protected mice against lethal H7N9 influenza virus infection. Early treatment with peramivir was found to be associated with better disease outcomes.
UR - http://www.scopus.com/inward/record.url?scp=84954531039&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84954531039&partnerID=8YFLogxK
U2 - 10.1128/AAC.01885-15
DO - 10.1128/AAC.01885-15
M3 - Article
C2 - 26369969
AN - SCOPUS:84954531039
SN - 0066-4804
VL - 59
SP - 7255
EP - 7264
JO - Antimicrobial Agents and Chemotherapy
JF - Antimicrobial Agents and Chemotherapy
IS - 12
ER -
